Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
复制标题
作者：
尽管已经提出了早期肺癌生存的预后基因表达特征，但对于临床应用，关键是在不同受试者人群和不同实验室中建立其性能。在这里，我们报告了一个大型的，训练测试，多站点盲验证研究，以表征442个肺腺癌的基因表达的基础上的几个预后模型的性能。提出的假设检查是否基因表达的微阵列测量单独或结合基本的临床协变量（阶段，年龄，性别）可以用来预测肺癌患者的总生存率。几个模型检查产生的风险评分，实质上与实际受试者的结果。大多数方法在临床数据上表现更好，支持在建立早期肺癌预后模型时结合使用临床和分子信息。这项研究还提供了最大的可用的一组微阵列数据与广泛的病理和临床注释肺腺癌。
Although prognostic gene expression signatures for survival in early stage lung cancer have been proposed, for clinical application it is critical to establish their performance across different subject populations and in different laboratories. Here we report a large, training-testing, multi-site blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The hypotheses proposed examined whether microarray measurements of gene expression either alone or combined with basic clinical covariates (stage, age, sex) can be used to predict overall survival in lung cancer subjects. Several models examined produced risk scores that substantially correlated with actual subject outcome. Most methods performed better with clinical data, supporting the combined use of clinical and molecular information when building prognostic models for early stage lung cancer. This study also provides the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas.